SCHEMBL464723

SCHEMBL464723

CCN(OC)OC.NS(=O)(=O)c1cccc2c1OCO2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.37
AMY1A P0DUB6 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
MAOB P27338 2/20 0.34
HTR2A P28223 2/20 0.33
HTR2C P28335 1/20 0.33
EPHB4 P54760 1/20 0.33
PKLR P30613 1/20 0.33
NAMPT P43490 1/20 0.33
PTGS1 P23219 2/20 0.33
PTGS2 P35354 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
CHRM1 P11229 1/20 0.32
ALDH1A1 P00352 2/20 0.32
POLB P06746 1/20 0.32
AOC3 Q16853 1/20 0.32
CA2 P00918 2/20 0.32
CA1 P00915 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL464734 0.83 ABCG2 (0.41) MAOBEPHB4NAMPTPTGS1PTGS2
SCHEMBL464724 0.77 ALDH1A1 (0.39) MGAMAMY1AGAASIMGAM2
SCHEMBL464731 0.76 MGAM (0.37) MGAMAMY1AGAASIMGAM2
SCHEMBL464729 0.75 PTGS1 (0.43) MAOBEPHB4NAMPTPTGS1PTGS2
SCHEMBL464740 0.71 PTGS2 (0.36) MGAMAMY1AGAASIMGAM2
SCHEMBL10664550 0.71 ACLY (0.44) PTGS1PTGS2SMN1; SMN2CA2CA1
SCHEMBL464730 0.71 EED (0.39) MGAMAMY1AGAASIMGAM2
SCHEMBL464746 0.69 EED (0.38) MGAMAMY1AGAASIMGAM2
SCHEMBL464814 0.69 CA12 (0.40) EPHB4PTGS1PTGS2SMN1; SMN2CHRM1
SCHEMBL464779 0.68 GSK3B (0.42) MAOBPKLRNAMPTPTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
EP-1686113-B1 Inhibitors of aspartyl protease VERTEX PHARMA (US) 2011-11-23 EP disclosed
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed
EP-1686113-A1 Inhibitors of aspartyl protease Vertex Pharmaceuticals Incorporated (US) 2006-08-02 EP disclosed
EP-1194404-B1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMA (US) 2006-05-03 EP disclosed
US-6878728-B1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICAL INCORPORATED (US) 2005-04-12 US disclosed
US-20040122000-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED. 2004-06-24 US disclosed
EP-1194404-A1 INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 2002-04-10 EP disclosed
WO-2000076961-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122000-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 MGAM 362/4885AMY1A 630/4885GAA 131/4885
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 MGAM 362/4885AMY1A 630/4885GAA 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.